IMVT250117P39000
- 0.00
- 0.000.00%
Immunovant Newsroom
Argenx Cut to Sell at Deutsche Bank on Valuation
Immunovant, Inc. (IMVT): The Biotech Stock With Biggest Upside Potential
Insider Trading: Immunovant's (IMVT) Major Investor Boosts Stake by $337M
Roivant Sciences Increases Stake in Immunovant With $336.9 Million Purchase
BofA Securities Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $45
Immunovant Is Maintained at Buy by B of A Securities
BofA Securities Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $45
Analysts' Top Healthcare Picks: Annexon Biosciences (ANNX), Immunovant (IMVT)
Immunovant Progresses in Autoimmune Therapy Development
Express News | Immunovant Inc - to Sell 22.5 Mln Shares at $20 Each in Pipe
Immunovant Announces $450 Million Private Placement
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not
Wolfe Research Downgrades Immunovant(IMVT.US) to Hold Rating
Wolfe Research Downgrades Immunovant to Peer Perform From Outperform
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth
Wells Fargo Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $45
Immunovant Is Maintained at Overweight by Wells Fargo
Immunovant Analyst Ratings
FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline With Promising Results and FDA Green Light for Pivotal Trial
Graves' Disease Pipeline Drug Research Report 2024 Featuring Viridian Therapeutics, Immunovant Sciences, Apitope International, Sling Therapeutics, and Novartis